Clinical Trials on Multiple System Atrophy, MSA in Russian Federation

Total 244 results

Biocad

Recruiting

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL) (BLUEBELL)

Spinal Muscular Atrophy (SMA)

Belarus, Russian Federation
Moscow Clinical Scientific Center

Recruiting

Epidemiology of Helicobacter Pylori Infection in Moscow

Gastric Cancer | Helicobacter Pylori Infection | Gastric Atrophy

Russian Federation
Research Institute for Complex Problems of Cardiovascular...

Unknown

Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant

Sarcopenia | Heart Failure, Systolic

Russian Federation
Research Institute for Complex Problems of Cardiovascular...

Unknown

Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance

Heart Failure | Sarcopenia | Peripheral Artery Disease | Exercise Intolerance

Russian Federation
NextGen Company Limited
Moscow State University of Medicine and Dentistry; Burnasyan Federal Medical...

Unknown

Gene-activated Matrix for Bone Tissue Repair in Maxillofacial Surgery

Jaw Fractures | Alveolar Bone Atrophy | Maxillofacial Bone Defects | Maxillofacial Bone Deformities | Bone Neoplasm, Benign | Disorders of Teeth and Jaw

Russian Federation
Biocad

Completed

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Completed

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Russian Federation
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Recruiting

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis (MIRANTIBUS)

Multiple Sclerosis

Russian Federation
OncoAtlas LLC
N.N. Blokhin National Medical Research Center of Oncology; Moscow MultidisciplinaryClinical...

Recruiting

Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy (BLOOMSI)

Cancer | Colorectal Cancer | Colorectal Cancer Metastatic | Colon Adenocarcinoma | MSI-H Colorectal Cancer | dMMR Colorectal Cancer

Russian Federation
Ivan S Moiseev

Terminated

The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood

Myeloma Multiple

Russian Federation
St. Petersburg State Pavlov Medical University

Terminated

Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
St. Petersburg State Pavlov Medical University

Recruiting

Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Petrovsky National Research Centre of Surgery

Recruiting

Efficacy and Safety of Hemoperfusion With Polymyxin B in Septic Shock Associated With Severe Endotoxemia in Cardiac Surgery Patients (РМХ vs SS) (РМХ vs SS)

Multiple Organ Dysfunction With Severe Endotoxemia

Russian Federation
St. Petersburg State Pavlov Medical University

Recruiting

AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Active, not recruiting

Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Bayer

Completed

Betaferon Use in Children and Adolescents With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
State Scientific Centre of Coloproctology, Russian...
The Loginov MCSC MHD; Pirogov National Medical and Surgical Center; Moscow City... and other collaborators

Recruiting

Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer (MSIRus22)

Colorectal Cancer | Lynch Syndrome | Hereditary Colorectal Cancer | MSI

Russian Federation
Russian Academy of Medical Sciences

Unknown

Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity (ANTMS)

Spasticity, Multiple Sclerosis, Stroke, Trauma

Russian Federation
National Research Center for Hematology, Russia

Unknown

MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis (MSC-CY)

Leukemia | Multiple Myeloma

Russian Federation
Human Stem Cell Institute, Russia
Genotarget

Enrolling by invitation

Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy in the RF (DYSF-RUS)

Dysferlinopathy | Miyoshi Myopathy | LGMDR2 | DMAT

Russian Federation
I.M. Sechenov First Moscow State Medical University

Completed

Periodontal Disease in Patients With Obstructive Sleep Apnea

Periodontal Diseases | Obstructive Sleep Apnea of Adult | Periodontal Pocket | Periodontal Attachment Loss

Russian Federation
St. Petersburg State Pavlov Medical University

Active, not recruiting

ASCT With Nivolumab in Patients With Multiple Myeloma

Multiple Myeloma

Russian Federation
Eli Lilly and Company
BioMS Technology Corp.

Completed

A Study for Patients With Relapsing Remitting Multiple Sclerosis (MINDSET01)

Relapsing Remitting Multiple Sclerosis

Serbia, Bulgaria, Poland, Russian Federation, Slovakia, Ukraine
Novartis Pharmaceuticals

Completed

An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

Belgium, Germany, Italy, Russian Federation, Poland, Bulgaria, Denmark
Hoffmann-La Roche

Active, not recruiting

A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (Rainbowfish)

Muscular Atrophy, Spinal

United States, Belgium, Brazil, Russian Federation, Australia, Taiwan, Poland
Celgene

Completed

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Multiple Myeloma

Russian Federation
Sensor Technology for Deafblind
Central Clinical Hospital under President Affairs; Deaf-Blind Support Foundation... and other collaborators

Completed

Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa (RU-RP)

Retinitis Pigmentosa | Usher Syndromes

Russian Federation
AveXis, Inc.
United BioSource, LLC

Recruiting

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy (SMA)

Japan, United States, Korea, Republic of, Israel, Greece, Ireland, Portugal, Russian Federation, Taiwan
Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
Sensor Technology for Deafblind
Deaf-Blind Support Foundation Con-nection; Federal State Budgetary Institution... and other collaborators

Completed

Clinical and Genetic Testing of Patients With Usher Syndrome

Retinitis Pigmentosa | Usher Syndrome | Congenital Deafness

Russian Federation
Hoffmann-La Roche

Withdrawn

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis (LEGATO)

Multiple Sclerosis

Russian Federation
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Multiple Myeloma | Plasmacytoma

China, Russian Federation
Novartis Pharmaceuticals

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis

Russian Federation
Mitsubishi Tanabe Pharma Corporation

Completed

Extension Study of MT-1303

Relapsing-remitting Multiple Sclerosis

Belgium, Bulgaria, Canada, Croatia, Czech Republic, Finland, Germany, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation, Ukraine, Czech Republic
Novartis Pharmaceuticals

Completed

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Relapsing-remitting Multiple Sclerosis | RRMS

Russian Federation, Ukraine, Czech Republic
GlaxoSmithKline

Completed

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Belgium, Germany, Russian Federation, Spain, Poland
Apitope Technology (Bristol) Ltd.
Aptiv Solutions; ClinStar, LLC

Completed

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

United Kingdom, Russian Federation
Nuron Biotech Inc.

Unknown

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing Remitting Multiple Sclerosis

Poland, Spain, Belarus, Bulgaria, Serbia, Ukraine, Russian Federation, Hungary, Italy, Croatia, Georgia, Lebanon
Celgene

Completed

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Multiple Myeloma

Ukraine, Russian Federation
Biocad

Recruiting

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma (DARVIVA)

Multiple Myeloma

Russian Federation
GeNeuro SA
Worldwide Clinical Trials; Institut de Recherches Internationales Servier; Les...

Completed

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS (CHANGE-MS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Ukraine, Germany, Spain, Bulgaria, Serbia, Russian Federation, Hungary, Italy, Croatia, Czechia, Estonia
GeNeuro SA
Worldwide Clinical Trials; Institut de Recherches Internationales Servier; Les...

Terminated

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis (ANGEL-MS)

Multiple Sclerosis, Relapsing-Remitting

Estonia, Bulgaria, Croatia, Czechia, Germany, Hungary, Italy, Poland, Russian Federation, Serbia, Spain, Ukraine
Genzyme, a Sanofi Company

Terminated

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

Relapsing-remitting Multiple Sclerosis

Russian Federation, United States, Canada, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Relapsing Multiple Sclerosis

Japan, Russian Federation
Hoffmann-La Roche

Completed

Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy (FIREFISH)

Muscular Atrophy, Spinal

Belgium, United States, China, Spain, Japan, France, Brazil, Croatia, Italy, Russian Federation, Saudi Arabia, Serbia, Switzerland, Turkey, Ukraine, Poland
Mitsubishi Tanabe Pharma Corporation

Completed

Dose-finding Study of MT-1303

Relapsing-remitting Multiple Sclerosis

Croatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

Multiple Sclerosis (MS)

United States, Lebanon, Spain, Sweden, Poland, Italy, Estonia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Korea, Republic of, Lithuania, Norway, Portugal, Romania, Russian Federation and more
Hoffmann-La Roche

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH)

Muscular Atrophy, Spinal

Belgium, United States, China, Spain, Japan, Canada, France, Poland, Brazil, Croatia, Italy, Russian Federation, Turkey, Germany, Serbia, United Kingdom

Clinical Trials on Multiple System Atrophy, MSA in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations